ArticleBMC urology2025
A novel equation synthesis for estimating resting energy expenditure in prostate cancer patients.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn accurate calculation of energy expenditure (REE) is necessary for estimating energy needs in malign prostate cancer. The purpose of this research was to evaluate the accuracy of the established novel equation for predicting REE in malign and benign prostate patients versus the accuracy of the previously used predictive equations based on REE measured by indirect calorimetry.
methodsThe study was conducted as a cross-sectional case-control study and between December 2020 and May 2021 with 40 individuals over the age of 40 who applied to the Urology Clinic of Gazi University Faculty of Medicine. Subjects with 41 malign prostate and 42 benign prostate patients were both over the age of 40 (65.3 ± 6.30 years) and recruited for the study. Cosmed-FitMate GS Indirect Calorimetry with Canopyhood (Rome, Italy) was used to measure REE. A full body composition analysis and anthropometric measurements were taken. CLINICAL TRIAL NUMBER: Not applicable.
resultsMalign prostate group PSA Total and measured REE values (4.93 ± 5.44 ng/ml, 1722.9 ± 272.69 kcal/d, respectively) were statistically significantly higher than benign group (1.76 ± 0.73 ng/ml, 1670.5 ± 266.76 kcal/d, respectively) (p = 0.022). Malign prostate group (MPG) and benign prostate group (BPG) have the highest percentage of the accurate prediction value of Eq. 80.9% (novel equation MPG) and 64.2% (novel equation BPG). The bias of the equations varied from - 36.5% (Barcellos II Equation) to 19.2% (Mifflin-St. Jeor equation) for the malign prostate group and varied from - 41.1% (Barcellos II Equation) to 17.7% (Mifflin-St. Jeor equation) in the benign prostate group. The smallest root mean squared error (RMSE) values in the malign and benign prostate groups were novel equation MPG (149 kcal/d) and novel equation BPG (202 kcal/d). The new specific equation for malign prostate cancer: REE = 3192,258+ (208,326* body weight (WT)) - (20,285* height (HT)) - (187,549* fat free mass (FFM)) - (203,214* fat mass (FM)) + (4,194* prostate specific antigen total (PSAT)). The new specific equation for the benign prostate group is REE = 615,922+ (13,094*WT). Bland-Altman plots reveal an equally random distribution of novel equations in the malign and benign prostate groups.
conclusionsPreviously established prediction equations for REE may be inconsistent. Utilising the PSAT parameter, we formulated novel energy prediction equations specific to prostate cancer. In any case, the novel predictive equations enable clinicians to estimate REE in people with malign and benign prostate groups with sufficient and most acceptable accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.